EUCTR2006-002688-26-IT进行中（未招募）不适用
A Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients with Stage IIIb-IV Non-Small Cell Lung Cancer (NSCLC) - NExUS
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- BAYER
- 入组人数
- 990
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?Age > 18 years old ?Stage IIIB (with cytologically confirmed malignant pleural or pericardial effusion) or Stage IV histological or cytological confirmation of NSCLC. (thoracentesis or pericardiocentesis is not necessary if a biopsy of the original tumor is available to confirm diagnosis of NSCLC). ?Patients with at least one measurable lesion. Lesions must be measured by CT-scan or MRI (Magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumors (RECIST, see Appendix 10.3) ?Life expectancy of at least 12 weeks ?Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose: ?Hemoglobin ³ 9.0 g/dl (³ 5.6 mmol/l) ?Absolute neutrophil count (ANC) ³ 1,500/mm3 ?Platelet count ³ 100,000/l ?Total bilirubin £ 1.5 x upper limit of normal ?ALT and AST £ 2.5 x upper limit of normal (£ 5 x upper limit of normal for patients with liver involvement of their cancer) ?Alkaline phosphatase £ 4 x upper limit of normal ?PT-INR (international normalized ratio of PT) /PTT < 1.5 x upper limit of normal ?Serum Creatinine ≤ 1.5 times the upper limit of normal. ?Ability to understand and the willingness to sign a written informed consent. A signed informed consent must be obtained prior to performing any study specific procedures. ?ECOG Performance Status of 0 or 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?History of cardiac disease: congestive heart failure >NYHA (New York Heart Association) class 2; active CAD (Coronary artery disease), MI (Myocardial Infarction) more than 6 months prior to study entry is allowed; cardiac arrhythmias requiring anti-arrhythmic therapy beta blockers or digoxin are permitted or uncontrolled hypertension. ?History of HIV (Human immunodeficiency virus) infection or chronic hepatitis B or C ?Active clinically serious infections (> grade 2 NCI-CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) version 3.0) ?Patients with seizure disorder requiring medication (such as steroids or anti-epileptics) ?Known brain metastasis. Patients with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis. ?History of organ allograft ?Patients with evidence or history of bleeding diathesis or coagulopathy ?Patients undergoing renal dialysis ?Cancer other than NSCLC within 5 years prior to start of study treatment EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, or superficial bladder tumors [Ta (Noninvasive tumor), Tis (Carcinoma in situ) & T1 (Tumor invades lamina propria)] ?Uncontrolled hypertension defined as systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg, despite optimal medical management. ?Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months ?Pulmonary hemorrhage/bleeding event > CTCAE Grade 2 within 4 weeks of first dose of study drug ?Any other hemorrhage/bleeding event > CTCAE Grade 3 within 4 weeks of first dose of study drug ?Serious, non-healing wound, ulcer, or bone fracture ?Uncorrected dehydration ?Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate birth control measures during the course of the trial. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate. ?Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results ?Known or suspected allergy to the investigational agent or any agent given in association with this trial ?Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study ?Patients unable to swallow oral medications ?Any malabsorption condition Excluded therapies and medications, previous and concomitant: ?Any prior systemic anticancer therapy including cytotoxic therapy, targeted agents, experimental therapy, adjuvant, or neo-adjuvant therapy for NSCLC ?Concomitant use of nephrotoxic drugs, ototoxic drugs, anticonvulsant, anti-gout treatment ?Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy will be allowed as described in the Prior and Concomitant Therapy section) ?Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug (bronchoscopy is allowed) ?Granuloctye colony stimulating factor (GCSF) or Granulocyte macrophage colony stimulating factor (GMCSF), within 3 weeks of study entry (these growth factors may be used during the study thereafter). ?Therapeutic anticoagulation with vitamin K antagonists such as warfarin, or wit
研究者
相似试验
尚未招募
Unknown
A clinical study to evaluatethe efficacy of JUVECOL K for period of 16 weeks in improving Knee Joint HealthCTRI/2024/07/070176aturetech co Ltd
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Paediatric (10 – 17 years old) Subjects with Type 2 DiabetesMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 DiabetesEUCTR2010-021057-39-BEovo Nordisk A/S21
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Paediatric (10 – 17 years old) and Adult Subjects with Type 2 DiabetesMedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 DiabetesEUCTR2010-021057-39-SIovo Nordisk A/S60
进行中（未招募）
不适用
A Randomized, Double-blind, Placebo Controlled Trial to Assess Safety/Tolerability, Pharmacokinetics & Pharmacodynamics of Liraglutide in Paediatric (10 – 17 years old) Subjects with Type 2 DiabetesType 2 DiabetesEUCTR2010-021057-39-GBovo Nordisk A/S21
进行中（未招募）
1 期
A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women with BI-RADS Breast Density Categories C or DBreast tissue density in women with BI-RADS Breast Density Categories C to DMedDRA version: 20.0 Level: LLT Classification code 10065307 Term: Breast density increased System Organ Class: 100000004848EUCTR2017-002906-10-ESBHR Pharma, LLC330